/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

CELULARITY INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2 0(0%) CELU at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 1.95
Highest Today 2.039
Today’s Open 2.039
Prev. Close 2.02
52 Week High 4.35
52 Week Low 1.00
Day’s Range: Low 1.95 High 2.039
52-Week Range: Low 1.00 High 4.35
1 day return -
1 Week return +2.53
1 month return +19.52
3 month return -14.4
6 month return -1.94
1 year return -6.04
3 year return -88.18
5 year return -98.07
10 year return -

Institutional Holdings

C V Starr & Co Inc 2.86

Vanguard Group Inc 1.87

Vanguard Total Stock Mkt Idx Inv 1.24

Vanguard Institutional Extnd Mkt Idx Tr 0.52

Geode Capital Management, LLC 0.51

BlackRock Inc 0.39

Fidelity Extended Market Index 0.26

State Street Corp 0.25

Citadel Advisors Llc 0.22

Valmark Advisers, Inc. 0.19

Royal Bank of Canada 0.15

Bank of America Corp 0.14

Biltmore Family Office, LLC 0.13

Northern Trust Corp 0.13

Group One Trading, LP 0.09

iShares Micro-Cap ETF 0.09

Keynote Financial Services, LLC 0.09

XTX Topco Ltd 0.08

Fidelity Total Market Index 0.08

Northern Trust Extended Eq Market Idx 0.07

NT Ext Equity Mkt Idx Fd - L 0.07

Fidelity Series Total Market Index 0.07

SIMPLEX TRADING, LLC 0.07

Two Sigma Investments LLC 0.06

NT Ext Equity Mkt Idx Fd - NL 0.05

Spartan Extended Market Index Pool F 0.05

Extended Equity Market Fund K 0.05

Renaissance Technologies Corp 0.05

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.04

IFP Advisors, LLC 0.04

Spartan Total Market Index Pool G 0.03

SBI Securities Co Ltd 0.03

Fidelity Nasdaq Composite Index 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

Vanguard Balanced Index Inv 0.01

Tower Research Capital LLC 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Vanguard U.S. Eq Idx £ Acc 0.01

BNYM Mellon SL Market Completion UC1 0.01

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 57.20 M

PB Ratio 9.8919

PE Ratio 0.0

Enterprise Value 123.30 M

Total Assets 132.68 M

Volume 99128

Company Financials

Annual Revenue FY24:22771000 22.8M, FY23:14788000 14.8M, FY22:17975000 18.0M, FY21:21335000 21.3M, FY20:14278000 14.3M

Annual Profit FY24:6755000 6.8M, FY23:3134000 3.1M, FY22:-1690000 -1.7M, FY21:11682000 11.7M, FY20:9346000 9.3M

Annual Net worth FY24:-196295000 -196.3M, FY23:-181408000 -181.4M, FY22:14192000 14.2M, FY21:-100118000 -100.1M, FY20:-208233000 -208.2M

Quarterly Revenue Q3/2025:5284000 5.3M, Q2/2025:5736000 5.7M, Q1/2025:18132000 18.1M, Q3/2024:9296000 9.3M, Q2/2024:12112000 12.1M

Quarterly Profit Q3/2025:3266000 3.3M, Q2/2025:494000 0.5M, Q1/2025:10789000 10.8M, Q3/2024:5413000 5.4M, Q2/2024:2503000 2.5M

Quarterly Net worth Q3/2025:-23073000 -23.1M, Q2/2025:-24524000 -24.5M, Q1/2025:-13293000 -13.3M, Q3/2024:-16098000 -16.1M, Q2/2024:9547000 9.5M

Fund house & investment objective

Company Information Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Organisation Biotechnology

Employees 123

Industry Biotechnology

CEO Dr. Robert Joseph Hariri M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow